NaQuinate is under clinical development by Haoma Medica and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NaQuinate’s likelihood of approval (LoA) and phase transition for Osteoporosis took place on 27 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NaQuinate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NaQuinate is under development for the treatment of osteoporosis and osteopenia. It is administered orally. It is a small molecule naturally occurring metabolite of vitamin K with low toxicity and high oral bioavailability.
Haoma Medica overview
Haoma Medica is a biotechnology company that focuses on the development of drugs for the treatment of osteopenia, osteoporosis, and blood clotting management. The company’s osteoporosis and osteopenia drugs include NaQuinate commercially known as Osteopura developed for low dose oral administration. Haoma Medica’s product, Osteopura preserves mass and bone architecture and is gender neutral by nature. The company’s products are in the preclinical stage of clinical trials. It has been granted patent rights for its product in the UK, the US, China, Japan, India, Australia, Hong Kong, Israel, and Russia. Haoma Medica is headquartered in London, Greater London, the UK.
Quick View NaQuinate LOA Data
|Highest Development Stage|